Searchable abstracts of presentations at key conferences in endocrinology

ea0035p577 | Endocrine tumours and neoplasia | ECE2014

Patient-reported outcomes associated with lanreotide Autogel (LAN-ATG) for symptom control of carcinoid syndrome in gastroenteropancreatic neuroendocrine tumour patients: results of SYMNET, a large International Multicentre Observational Study

Ruszniewski Philippe , Caplin Martyn , Valle Juan , Lombard-Bohas Catherine , Poston Graeme , Perros Petros , Holubec Lubos , Fave Gianfranco Delle , Smith Denis , Niccoli Patricia , Maisonobe Pascal , Atlan Philippe

Introduction: Somatostatin analogues are widely used to reduce the incidence and severity of carcinoid syndrome symptoms. However, their impact on patients’ satisfaction with symptom control needs further investigation. SYMNET was a large international multicentre observation study that assessed PROs during LAN-ATG treatment of carcinoid syndrome in gastroenteropancreatic neuroendocrine tumour (GEP–NET) patients.Methods: At routine clinic visit...

ea0035p578 | Endocrine tumours and neoplasia | ECE2014

Antiproliferative effects of lanreotide Autogel in patients with enteropancreatic neuroendocrine tumours: results of CLARINET, a large international phase 3 study

Caplin Martyn , Ruszniewski Philippe , Pavel Marianne , Cwikla Jaroslaw , Phan Alexandria , Raderer Markus , Sedlackova Eva , Cadiot Guillaume , Wall Lucy , Rindi Guido , Langley Alison , Blumberg Joelle

Introduction: Data demonstrating antiproliferative effects of somatostatin analogs (SSAs) in enteropancreatic NETs are limited; only one prospective trial so far has shown this for patients with midgut tumors and low hepatic tumor load (HTL). CLARINET is the first large phase 3, randomized, placebo-controlled trial evaluating such effects for the SSA lanreotide in patients with non-functioning enteropancreatic NETs.Methods: Patients who had well/moderate...